What are the indications, dosing, contraindications, and monitoring recommendations for canagliflozin in adults with type 2 diabetes mellitus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Canagliflozin: Clinical Overview

Canagliflozin is an SGLT2 inhibitor with FDA-approved indications extending beyond glycemic control to include cardiovascular and renal risk reduction in adults with type 2 diabetes. 1

FDA-Approved Indications

Canagliflozin is indicated for 1:

  • Glycemic control: As adjunct to diet and exercise in adults and pediatric patients ≥10 years with type 2 diabetes
  • Cardiovascular risk reduction: To reduce major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke) in adults with type 2 diabetes and established CVD
  • Renal protection: To reduce risk of ESKD, doubling of serum creatinine, CV death, and heart failure hospitalization in adults with type 2 diabetes and diabetic nephropathy with albuminuria >300 mg/day

Important Limitations

Canagliflozin is not recommended for glycemic control in type 1 diabetes or in type 2 diabetes with eGFR <30 mL/min/1.73 m² (likely ineffective due to mechanism of action). 1

Dosing Recommendations

Standard Dosing 2, 1

For glycemic control in adults and pediatric patients ≥10 years:

  • Starting dose: 100 mg orally once daily before first meal
  • Titration: May increase to 300 mg once daily in patients tolerating 100 mg who have eGFR ≥60 mL/min/1.73 m² and require additional glycemic control

For cardiovascular and renal indications in adults:

  • Recommended dose: 100 mg orally once daily
  • No dose titration needed for CV or renal benefits—the 100 mg dose tested in outcomes trials provides maximal benefit for these endpoints 2

Renal Dose Adjustments 2, 3

  • eGFR ≥60 mL/min/1.73 m²: No adjustment required; may use up to 300 mg for glycemic control
  • eGFR 30-59 mL/min/1.73 m²: Maximum 100 mg daily (glycemic efficacy reduced but CV/renal benefits maintained)
  • eGFR <30 mL/min/1.73 m²: Not recommended for initiation; however, continuation may be considered for CV/renal benefits until dialysis 4

Critical nuance: While glycemic benefits diminish below eGFR 45 mL/min/1.73 m², cardiovascular and renal benefits persist down to eGFR 30 mL/min/1.73 m². 3, 5 Recent evidence suggests continuation even when eGFR falls <20 mL/min/1.73 m² maintains benefit without additional safety concerns. 4

Contraindications 2, 3, 1

  • History of serious hypersensitivity reaction to canagliflozin
  • eGFR <30 mL/min/1.73 m² (for initiation)

Cautions and Special Populations

Volume Depletion 2, 3

Before initiating canagliflozin, assess and correct volume status, particularly in:

  • Patients with renal impairment
  • Elderly patients
  • Those on loop diuretics
  • Patients with low systolic blood pressure

Consider stopping or reducing diuretic dose when starting therapy.

Amputation Risk 2, 3

Use with extreme caution in patients with:

  • Prior amputation history
  • Severe peripheral neuropathy
  • Severe peripheral vascular disease
  • Active diabetic foot ulcers or soft tissue infections

Monitor closely for lower limb infections, ulcerations, and soft tissue infections. Discontinue if these occur.

Bone Fracture Risk 2, 3

Canagliflozin specifically (not other SGLT2 inhibitors) has shown increased fracture incidence. Consider fracture risk factors before initiating, particularly in patients with osteoporosis history.

Perioperative Management 2, 1

Discontinue canagliflozin at least 3 days before planned surgery or procedures with prolonged fasting to prevent postoperative ketoacidosis.

Hypoglycemia Risk 2, 3

When combining with insulin or insulin secretagogues:

  • Reduce insulin dose by ~20% when starting canagliflozin if HbA1c well-controlled or history of frequent hypoglycemia
  • Consider weaning or stopping sulfonylureas/glinides

Adverse Effects to Monitor 2

Common (≥5%):

  • Female genital mycotic infections
  • Urinary tract infections
  • Increased urination

Serious but less common:

  • Euglycemic diabetic ketoacidosis: Monitor for ketoacidosis regardless of blood glucose level, especially in vulnerable patients
  • Fournier's gangrene: Assess patients with genital/perineal pain, tenderness, erythema, swelling with fever—institute prompt treatment if suspected
  • Urosepsis and pyelonephritis: Evaluate and treat UTI signs/symptoms promptly
  • Lower limb ulcerations and soft tissue infections: Specific to canagliflozin

Clinical Context and Guideline Recommendations

Heart Failure 6, 7

In adults with type 2 diabetes and heart failure (HFrEF or HFpEF), an SGLT2 inhibitor is recommended for glycemic management and prevention of HF hospitalizations, irrespective of A1C level.

Chronic Kidney Disease 6, 7, 5

In adults with type 2 diabetes and CKD (eGFR 20-60 mL/min/1.73 m² and/or albuminuria), an SGLT2 inhibitor should be used for:

  • Minimizing CKD progression
  • Reducing cardiovascular events
  • Reducing HF hospitalizations

This recommendation applies irrespective of baseline A1C—the decision to use canagliflozin for CV/renal protection should be independent of glycemic targets. 5

The CREDENCE trial specifically demonstrated canagliflozin's renal benefits in patients with UACR 300-5,000 mg/g and eGFR 30-90 mL/min/1.73 m². 5

Established Cardiovascular Disease 2, 3

The CANVAS/CANVAS-R trials demonstrated canagliflozin reduces 3-point MACE (HR 0.86,95% CI 0.75-0.97) in patients with type 2 diabetes and established CVD. 3

Monitoring Recommendations

Before initiation:

  • Assess renal function (eGFR)
  • Assess volume status
  • Evaluate for peripheral vascular disease, neuropathy, foot ulcers

During therapy:

  • Monitor renal function as clinically indicated
  • Monitor for signs/symptoms of volume depletion
  • Monitor for genital/urinary infections
  • Monitor for lower limb complications (specific to canagliflozin)
  • Consider ketone monitoring in at-risk patients

Laboratory considerations:

  • Canagliflozin may increase LDL-C levels—monitor lipid panel
  • May cause modest increases in serum creatinine initially (hemodynamic effect, not true kidney injury)

Key Clinical Pearls

The 100 mg dose provides near-maximal cardiovascular and renal benefits—this is the dose tested in major outcomes trials and should be the standard for CV/renal indications. 2 The 300 mg dose offers additional glycemic benefit but no incremental CV/renal protection.

Continue canagliflozin even as eGFR declines below 30 mL/min/1.73 m² for ongoing CV/renal benefits until dialysis or transplantation, despite loss of glycemic efficacy. 4

Canagliflozin has unique amputation and fracture signals not consistently seen with other SGLT2 inhibitors—patient selection and monitoring are critical. 3

References

Related Questions

Can performing 100 repetitions of moderate-to-heavy resistance exercises on large muscle groups every other day for 15 minutes improve insulin sensitivity and help manage pre-diabetes?
For a 19‑year‑old with type 1 diabetes, weight 86 kg, creatinine 0.74 mg/dL, GFR > 90 mL/min, bicarbonate 17 mmol/L, anion gap 13, currently on metformin 750 mg daily and insulin glargine (Lantus) 15 U at 8 am and 35 U at 8 pm with carbohydrate‑to‑insulin ratios of 1 U per 6 g carbs at breakfast and 1 U per 7 g carbs at lunch/dinner and an insulin‑sensitivity factor of 25 mg/dL per U, and blood glucose values of 184 mg/dL (8 am), 220 mg/dL (noon), 262 mg/dL (5 pm), 237 mg/dL (10 pm), and 97 mg/dL (4 am), what should the morning and evening Lantus doses be and what should the insulin‑sensitivity factor and insulin‑to‑carbohydrate ratios be adjusted to?
For a 19‑year‑old patient with type 1 diabetes weighing 86.2 kg who is currently taking insulin glargine (Lantus) 12 U at 08:00 and 35 U at 20:00 and uses insulin‑to‑carbohydrate ratios of 1 U per 5 g carbs for breakfast and lunch and 1 U per 6 g carbs for dinner, what should the basal Lantus dose and insulin‑to‑carbohydrate ratio be adjusted to?
What is the clinical significance of a +1 glucose result on a urine dipstick and how should it be evaluated?
During a 100‑gram oral glucose tolerance test, my 180‑minute glucose level was 39 mg/dL, yet my home glucose measurements are within normal limits—what does this finding indicate and how should it be managed?
In a patient with chronic pulmonary sarcoidosis who remains symptomatic or steroid‑dependent despite an adequate trial of oral prednisone, how should leflunomide be initiated, dosed, monitored, and what are the contraindications?
A patient on mechanical ventilation is desaturating; what immediate management steps should be taken?
Can an adult develop shingles after exposure to a child with chickenpox?
Is norethindrone acetate safe for a 14‑year‑old adolescent?
Can carvedilol be initiated in a patient with a resting heart rate of 60 beats per minute?
What are the typical symptoms and clinical presentation of piriformis syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.